HIV Glycoprotein 41 [BGAL], recombinant protein from E. coli
Recombinant HIV-I transmembrane glycoprotein gp41, b-galactosidase-tagged
Immunoreactive with sera of HIV-infected individuals.
> 95%, as determined by SDS-PAGE.
Lyophilized from Imidasole 20mM, pH 7, 0; DTT 10 mM; NaCl 150 mM; urea 8 M
2-8°C short term, -20°C long term
The human immunodeficiency virus (HIV) is a lentivirus (slowly replicating retrovirus) that causes the acquired immunodeficiency syndrome (AIDS), a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. Without treatment, average survival time after infection with HIV is estimated to be 9 to 11 years, depending on the HIV subtype. Infection with HIV occurs by the transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk. Within these bodily fluids, HIV is present as both free virus particles and virus within infected immune cells.
Entry of human immunodeficiency virus (HIV- 1) into target T lymphocytes is known to be mediated by the viral envelope glycoproteins gp120/gp41. The glycoprotein gp41 is thought to form a six-helix bundle during viral fusion with the target cell. This bun
Env; Env polyprotein; Envelope glycoprotein gp160; Envelope Protein gp120; Glycoprotein 41; GP120; gp41; Human Immunodeficiency Virus 1; Human Immunodeficiency Virus Type 1 gp41; TM; Transmembrane protein; HIV1 gp41